NASDAQ:PRLD - Prelude Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $38.33
  • Forecasted Upside: -18.28 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$46.91
▼ -1.73 (-3.56%)
1 month | 3 months | 12 months
Get New Prelude Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRLD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRLD

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$38.33
▼ -18.28% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Prelude Therapeutics in the last 3 months. The average price target is $38.33, with a high forecast of $40.00 and a low forecast of $37.00. The average price target represents a -18.28% upside from the last price of $46.91.
Hold
The current consensus among 3 polled investment analysts is to hold stock in Prelude Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/24/2020

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2020Bank of AmericaDowngradeBuy ➝ NeutralHigh
i
11/12/2020Morgan StanleyBoost Price TargetEqual Weight$34.00 ➝ $38.00Low
i
10/20/2020Bank of AmericaInitiated CoverageBuy$40.00High
i
10/20/2020Morgan StanleyInitiated CoverageEqual Weight$34.00High
i
10/20/2020The Goldman Sachs GroupInitiated CoverageNeutral$37.00High
i
(Data available from 11/24/2015 forward)
Prelude Therapeutics logo
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.
Read More

Today's Range

Now: $46.91
$46.30
$51.33

50 Day Range

MA: N/A

52 Week Range

Now: $46.91
$23.69
$57.67

Volume

102,217 shs

Average Volume

180,167 shs

Market Capitalization

$2.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A